Methods	Randomized blinded, placebo-controlled clinical trial (little information about study methods)
Participants	26 women with gestational age between 27-37 weeks diagnosed with HELLP syndrome (criteria for diagnosis not clear). Exclusions: women with chorioamnionitis.
Interventions	Intervention group: (13) 10 mg dexamethasone IV every 12 hrs (2 doses) then 5 mg every 12 hrs (2 doses), total dose of 30 mg over 36 hours Control group: (13) no corticosteroid. All women were given a 6 g dose of magnesium sulfate (approximately 1.5 g/hr). All women gave birth within 12 hours
Outcomes	MAP, urinary output, serum glutanic aspartate aminotransferase (AST), alamine aminotransferase (ALT), LDH, and platelet count
Notes	Results were reported in graphs for platelet count, ALT levels, LDH levels and urine output. Not in a form in which we can enter results into RevMan ALT was listed as being measured along with AST but results for ALT were not reported in the results
Risk of bias
Item	Authors’ judgement	Description
Adequate sequence generation?	Unclear	Not stated (risk of bias assessment from translation notes).
Allocation concealment?	Unclear	“sealed envelopes were distributed randomly to patients” (translation notes)
Blinding? All outcomes	Unclear	Not clear whether blinding or partial blinding was attempted
Incomplete outcome data addressed? All outcomes	Yes	No attrition or withdrawals reported.
Free of other bias?	Yes	No baseline imbalance apparent.
Overall risk of bias?	Unclear	Risk of bias assessment from translation notes. Possible selection bias (randomization methods not clear). Possible performance bias (there is no mention of blinding or use of a placebo)